The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.
MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE
申请人:Global Blood Therapeutics, Inc.
公开号:EP3860975A1
公开(公告)日:2021-08-11
MODULATORS OF HEMOGLOBIN
申请人:Global Blood Therapeutics, Inc.
公开号:US20200140384A1
公开(公告)日:2020-05-07
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.
[EN] MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE<br/>[FR] MODULATEURS DE L'HÉMOGLOBINE POUR LE TRAITEMENT DE LA DRÉPANOCYTOSE
申请人:GLOBAL BLOOD THERAPEUTICS INC
公开号:WO2020072377A1
公开(公告)日:2020-04-09
The present disclosure relates to compounds of the general formula (I) and pharmaceutical compositions containing them. The compounds are suitable as modulators of hemoglobin and thus useful in treating disorders mediated by hemoglobin such as sickle cell disease.